Single-Cell RNA Sequencing Service for Neuroinflammatory Cell Involved in ICANS

Unlock Neuroimmune Insights – Advance Your Therapy Development!

Immune effector cell–associated neurotoxicity (ICANS) is a severe neurotoxic effect observed in patients receiving immune cell therapies such as CAR T-cell treatment. Understanding the complex neuroimmune interactions underlying ICANS remains a significant hurdle. Recent studies applying single-cell transcriptomics have highlighted the importance of dissecting neuroinflammatory cell populations at single-cell resolution to identify pathogenic subsets, transcriptional programs, and cytokine signaling patterns. These findings validate the power of Creative Biolabs' specialized sequencing service in driving targeted innovations in neuroimmune therapy development.

Are you currently facing the challenge of poorly understood mechanisms behind ICANS, inconsistent biomarkers, or ineffective therapeutic targets for neuroinflammation? Our single-cell RNA sequencing service of neuroinflammatory cell involved in ICANS helps you uncover actionable cellular signatures and regulatory pathways through high-resolution single-cell transcriptomics, enabling more precise intervention strategies in neuroimmune disorders.

Our service delivers real, actionable insights to accelerate your neuroinflammation research and immunotherapy development:

• Precise Cell-Type Identification: Detect rare but functionally critical neuroinflammatory populations driving ICANS.
• Translational Value: Gain patient-specific expression profiles that can be converted into drug targets or diagnostic markers.
• Data Interpretation Support: Receive high-impact visualizations and analytical reports for regulatory submission or publication.

Learn How We Can Support You – Schedule a Consultation

Strategies

Workflow

Required Starting Materials

• Cryopreserved cerebrospinal fluid (≥1 million cells preferred)
• Peripheral blood mononuclear cells from ICANS or CAR T-treated cohorts
• Patient metadata: therapy timeline, neurological grading, concurrent cytokine panels

Highlights

Targeted for ICANS Neurotoxicity

Unlike general single-cell services, our solution is purpose-built for dissecting neuroinflammatory mechanisms specific to ICANS, integrating curated immune–neuro datasets and disease-relevant markers (e.g., IL-1β, GM-CSF, CCR2), providing high interpretability in translational neuroimmunology studies.

Ultra-Deep Cell Typing of CNS-Associated Cells

Our pipeline distinguishes fine-grained subsets such as activated microglia, perivascular macrophages, and infiltrating CCR5+ T cells, enabling insights into cellular crosstalk that contributes to blood-brain barrier (BBB) compromise and neuronal dysfunction.

Pathway-Driven Biomarker Discovery

We don't stop at cell clustering—our team delivers transcriptional network maps, pinpointing converging inflammatory pathways (e.g., TNF–NFκB, interferon-stimulated genes) that may serve as druggable targets or patient risk classifiers.

Dedicated Bioinformatics Support

Our experienced immuno-neuro bioinformaticians provide 1:1 data review sessions, explain complex findings, and support integration into broader therapeutic or diagnostic programs.

Discover the Creative Biolabs Difference – Request Your Quote Today

Customer Reviews

• Identified Key IL-1 Signatures
  Using Creative Biolabs' ICANS scRNA-seq service in our research has significantly improved our identification of IL-1–producing monocyte subsets predictive of severe neurotoxicity. May 2025, Dr. Lis**
• Clarified Immune Trajectories
  The data provided helped us uncover dynamic changes in CD8+ T cell states over the course of CAR therapy, enabling precise timing for interventional trials. April 2025, Dr. Jef**
• Biomarker Validated in CSF
  This service allowed us to correlate specific microglial signatures with early ICANS scores, something we couldn't detect via bulk RNA-seq or flow cytometry. January 2025, Dr. Wan**

Publication

In patients experiencing ICANS following CAR T-cell therapy, differential gene expression analysis reveals distinct transcriptional alterations across six key immune cell types when compared to idiopathic intracranial hypertension (IIH). Multiple pro-inflammatory genes, including CXCL8, IL1B, and CCL3, are notably upregulated, particularly within monocytes and CD8+ T cells. Concurrent downregulation of regulatory or homeostatic genes is observed, suggesting a shift toward a heightened inflammatory state. These findings highlight cell type–specific immune activation patterns associated with ICANS onset and support the role of dysregulated cytokine signaling in its pathogenesis.

Fig.1 Differential expression reveals gene upregulation and downregulation across six cell types in ICANS onset versus IIH.¹

FAQs

Extended Services

Creative Biolabs delivers precision solutions in neuroimmune research through high-resolution transcriptomics. Our single-cell RNA sequencing service of neuroinflammatory cell involved in ICANS is tailored to support your discovery, validation, and therapeutic development needs.

Get in Touch to Start Designing Your Custom Study Today

Reference

1. Lu, I-Na, et al. "The CXCL16/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy." Genome Medicine 17.1 (2025): 1-14. DOI: 10.1186/s13073-025-01498-6. Distributed under Open Access license CC BY 4.0, without modification.